FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics
This trial, using Filament Health’s botanical drug candidates, is the first to assess the direct administration of psilocin.
Psychedelic Spotlight News
Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!
Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.
On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.
This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.
Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Psychedelics #CMPS
Psychedelic Mom and Therapist Explains How Giving Birth Was Like a ‘Wild Acid Trip’
Kate Kincaid, who specializes in psychedelic integration and ketamine-assisted therapy, appears on the premiere of our new series “Spotlight in Focus” to share parallels between labor and tripping on psychedelics.
Detroit Voters Decriminalize Plant Psychedelics
As the decriminalization movement sweeps through Michigan, Detroit becomes the largest city in the state to decriminalize entheogenic plants.
Interview with Awais Spall, Functional Diagnostic Nutrition Practitioner at Integrative Oasis
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
TRIPP Wants You to ‘Be Here Now,’ With or Without Ram Dass
Psychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher’s iconic book.
Lil Nas X Says Psychedelics Helped Him ‘Open Up’ to Write Debut Album ‘Montero’
Pop star says in new interview that tripping on psilocybin enabled him, for the first time, to “write actual stories about my life and put it into my music.”
Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser
“Something that people used to speak about only in whispers is now standard policy,” says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.
Parents Are Very Open to Ketamine Therapy for Kids, Study Finds
“As parents maintain decision-making capacity of their child’s medical care, parental consent is a key factor in the adoption of new treatments for adolescents,” study authors explain.
Are We Being Exposed to Psychedelics More Than Ever Before? Survey Says…It’s Complicated
A study of American newspaper mentions of psychedelics doesn’t stack up to what leaders in the industry are observing in the media landscape at large.
End of content
End of content